Key result
Sofosbuvir-velpatasvir plus GS-9857 achieves 100% SVR12 in treatment-naive and DAA-experienced patients.
Why the study?
Does sofosbuvir-velpatasvir plus GS-9857 improve sustained virologic response in patients with genotype 1 hepatitis C virus infection?
RCT (n=197)
Open-label
Yes
Does sofosbuvir-velpatasvir plus GS-9857 improve sustained virologic response in patients with genotype 1 hepatitis C virus infection?
Answers are grounded in this paper and cite their sources.
8 to 12 weeks of sofosbuvir-velpatasvir plus GS-9857 is safe and highly effective for achieving sustained virologic response in patients with genotype 1 hepatitis C virus infection, regardless of prior DAA treatment or compensated cirrhosis.
BACKGROUND & AIMS: The best regimen to re-treat patients who do not respond to direct-acting antivirals (DAAs) and the feasibility of further shortening regimens is unclear. We assessed the efficacy and safety of the combination of the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 in patients with hepatitis C virus genotype 1 infection. METHODS: We performed an open-label trial at 32 sites in the United States and at 2 sites in New Zealand of 197 patients with genotype 1 hepatitis C virus infection, with or without compensated cirrhosis, who were treatment-naive or were treated previously with a DAA. Between March 2, 2015, and September 1, 2015, patients received sofosbuvir-velpatasvir (400 mg/100 mg in a fixed-dose combination) plus GS-9857 (100 mg) once daily for 6-12 weeks, plus ribavirin for 1 treatment group consisting of treatment-naive patients with cirrhosis. The primary end point was sustained virologic response 12 weeks after treatment (SVR12). RESULTS: Among treatment-naive patients without cirrhosis, 71% (24 of 34; 95% confidence interval [CI], 53-85) achieved SVR12 after 6 weeks of treatment and 100% (36 of 36; 95% CI, 90%-100%) achieved SVR12 after 8 weeks of treatment. Among treatment-naive patients with cirrhosis, 94% (31 of 33; 95% CI, 80-99) achieved SVR12 after 8 weeks of treatment and 81% (25 of 31; 95% CI, 63-93) achieved SVR12 after 8 weeks of treatment with ribavirin. Among DAA-experienced patients treated for 12 weeks, 100% without cirrhosis (31 of 31; 95% CI, 89-100) and 100% with cirrhosis (32 of 32; 95% CI, 89-100) achieved SVR12. The most common adverse events were headache, diarrhea, fatigue, and nausea. One patient (<1%) discontinued treatment because of adverse events. CONCLUSIONS: In a phase 2 open-label trial, we found 8 weeks of treatment with sofosbuvir-velpatasvir plus GS-9857 to be safe and effective in treatment-naive patients; 12 weeks was safe and effective in patients previously treated with DAAs. The combination was safe and effective in patients with or without compensated cirrhosis. Clinicaltrials.gov no: NCT02378935.
No takes yet. Share an insight, caveat, or question.
Lawitz et al. (2016) conducted an RCT in Genotype 1 Hepatitis C Virus Infection (n=197). Sofosbuvir, velpatasvir, and GS-9857 was evaluated on sustained virologic response 12 weeks after treatment (SVR12). Sofosbuvir-velpatasvir plus GS-9857 achieved 100% SVR12 after 8 weeks in treatment-naive patients without cirrhosis, and 100% SVR12 after 12 weeks in DAA-experienced patients.
Synapse has enriched 10 related papers. Consider them for comparative context: